Professor Gregory Mattingly outlines how REXULTI® works as a treatment of schizophrenia, and discusses the advantages of using an agent that modulates serotonin and dopamine receptors.1*
*Preclinical data do not necessarily predict clinical effects.
REXULTI PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia
Please review Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:
REXULTI® is a registered trademark of H. Lundbeck A/S. REXULTI® is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.
